Immediate Impact
3 by Nobel laureates 1 from Science/Nature 57 standout
Citing Papers
The hallmarks of cancer immune evasion
2024 Standout
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
Works of Satoshi Tamada being referenced
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
2020 Standout
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Satoshi Tamada | 937 | 567 | 634 | 70 | 1.7k | |
| Roger Lacave | 577 | 637 | 588 | 72 | 1.7k | |
| Shotaro Naito | 449 | 883 | 542 | 78 | 2.0k | |
| Badar M. Mian | 813 | 709 | 518 | 57 | 1.9k | |
| Sue C. Heffelfinger | 784 | 430 | 384 | 52 | 2.0k | |
| Shinji Sumiyoshi | 722 | 437 | 476 | 60 | 1.8k | |
| Takashi Ohigashi | 912 | 537 | 459 | 93 | 2.1k | |
| András Szabó | 440 | 1124 | 453 | 39 | 1.9k | |
| Hannes Neuwirt | 475 | 778 | 542 | 60 | 1.7k | |
| Stephan Macher‐Goeppinger | 519 | 1107 | 430 | 59 | 2.0k | |
| Toshitaka Maeno | 852 | 785 | 257 | 92 | 2.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...